Skyrizi achieves consistent results in plaque psoriasis across racial, ethnic groups

NEW YORK — Skyrizi exhibited efficacy across racial and ethnic groups for the treatment of moderate to severe plaque psoriasis, according to a presentation at the Skin of Color Update 2023 meeting.
“When we think about moderate to severe psoriasis, we have a lot of biologic options for treatment,” Raj Chovatiya, MD, PhD, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, told Healio. “And [Skyrizi (risankizumab, AbbVie)] is one of the most efficacious ones we have that has pretty infrequent dosing and really good short- and

NEW YORK — Skyrizi exhibited efficacy across racial and ethnic groups for the treatment of moderate to severe plaque psoriasis, according to a presentation at the Skin of Color Update 2023 meeting.
“When we think about moderate to severe psoriasis, we have a lot of biologic options for treatment,” Raj Chovatiya, MD, PhD, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, told Healio. “And [Skyrizi (risankizumab, AbbVie)] is one of the most efficacious ones we have that has pretty infrequent dosing and really good short- and